Press release
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the
About this update from Natera, Inc.
[{"type":"text","content":"\nHighlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 – 6, 2023. Signatera and Natera’s circulating tumor DNA (ctDNA) technology will be featured across a wide variety of cancers, including colorectal (CRC), lung, bladder, esophageal, pancreatic, melanoma, sarcoma and cholangiocarcinoma.\n\n\n“We are grateful for the opportunity to share new data at ASCO that furthers Natera’s leadership in the ctDNA space,” said Minetta Liu, M.D., chief medical officer of oncology at Natera. “These presentations provide additional support for the role of ctDNA in predicting patient outcomes and assessing treatment response in both common and rare cancers. Use of data generated from our ctDNA technology to broaden our understanding of tumor biology is also demonstrated. We are thrilled to collaborate with the oncology community in pursuit of better outcomes for patients living with cancer.”\n\n\nHighlights from selected abstracts include:\n\n\nAbstract #9022 | NSCLC | Poster Discussion\nctDNA dynamics and survival outcomes in patients with advanced non-small cell lung cancer and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab vs chemotherapy\n\n\nResults will be presented from the Phase 3 EMPOWER-Lung 1 study of 175 NSCLC patients randomized to chemotherapy vs cemiplimab. In patients treated with cemiplimab, ctDNA increase was associated with the highest risk of death, while clearance and a >90% decrease in ctDNA were associated with significantly improved overall survival.\n\n\nAbstract #3521 | CRC | Poster Discussion\nctDNA dynamics as an early predictor of recurrence in patients with radically resected CRC: Updated results from GALAXY study in the CIRCULATE-Japan\n\n\nExpanded analysis with 2,083 stage II-IV patients shows a strong hazard ratio at 4 weeks post surgery (HR 12.0; p","length":2945,"tagName":"div"}]